— 93 Percent of Patients Treated with Investigational KTE-X19 Achieved Response, Including 67 Percent with a Complete Response — — Findings Support Regulatory Filings for Kite’s Second CAR T Cell Therapy — — Data Presented at American...
Vedanta Biosciences, Inc. (Vedanta Biosciences, Vedanta or the Company), a clinical-stage biopharmaceutical company developing a new category of therapies for immune-mediated diseases based on defined bacterial consortia, today announced the initiation of a...
Mark Terry for Biospace writes: It was, as usual, a pretty busy week in clinical trial news. Here’s a look. ASLAN Pharmaceuticals announced positive preliminary data from the lowest dose cohort of its trial of ASLAN004 for moderate-to-severe atopic dermatitis....
CAMBRIDGE, England & MOSCOW–(BUSINESS WIRE)–IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been informed that International Biotechnology Center (IBC) Generium, a leading Russian biopharmaceutical...
NORCROSS, Ga., Dec. 09, 2019 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc.(NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper highlighting the results of its NASH-CX Phase 2 clinical trial in NASH...
Email
Text